3 biotech stocks to watch in 2025

The biotechnology sector faced a challenging environment in 2024. Yet there are companies that many analysts believe could be attractive investments in 2025. Which companies are they?

Biotech: High risk, high reward

The biotech sector is known for its volatility. In 2024, it has been impacted by high interest rates and a volatile healthcare environment. Still, the right investment can yield high profits, especially through breakthrough drugs or research successes.

Avadel Pharmaceuticals $AVDL: Opportunity in a down stock

Avadel Pharmaceuticals specializes in the treatment of narcolepsy through its core product Lumryz. The company achieved $50 million in revenue in the last quarter of 2024, representing a year-over-year increase of more than 150%. Still, the stock fell significantly due to a lower-than-expected outlook for 2025 ($240-260 million).

Avadel faces a challenge in the form of patient churn, but is working to increase Lumryz adoption. At the same time, it continues to progress through Phase 3 clinical trials and has over $70 million in cash, giving it room to improve. For adventurous investors who believe in long-term growth, the decline of more than 48% over the past year may be a buying opportunity.

Sana Biotechnology $SANA: Revolutionizing the treatment of type 1 diabetes

Sana Biotechnology is a gene and cell therapy company whose stock is down 48.5% in 2024. Sana recently released breakthrough data from a clinical trial focused on allogeneic transplantation - the transfer of healthy donor cells without the need for immunosuppressive drugs. This approach could revolutionize the treatment of type 1 diabetes and other diseases.

Following the news, Sana's stock more than doubled in value, rising 65% in the past month. Analysts estimate growth of up to 350% with a target price of $14.25, making the company an attractive investment with high potential.

ADMA Biologics $ADMA: Rapid revenue and earnings growth

ADMA Biologics has seen significant success in 2024 due to the commercialization of its products. Third-quarter revenue grew 78% to $120 million, while net income rose 1,300% to nearly $36 million.

The company expects further revenue growth in 2025 to over $485 million and in 2026 to over $600 million. It plans to reach $1 billion in annual sales by 2030. Although ADMA stock is up 228% over the past year, analysts still see potential for further growth.

Disclaimer: You will find a lot of inspiration on Bulios, but stock selection and portfolio construction is up to you, so always do a thorough analysis of your own.

Source: marketbeat